Avacta
Next gen pre|CISION data unveiled at triple meetingOxford BioDynamics
Commercialising cutting edge diagnosticsScancell
SCOPE readouts in sight; SCIB1 data in Q424ANGLE
H124: renewed near-term focus on Pharma ServicesAvacta
H124 interims: a time to reflect on progress achievedArecor Therapeutics
H124: Focus on next steps for diabetes and obesityHUTCHMED
Flow of catalysts continues, with more into 2025Scancell
FY24: Cash to deliver on key clinical catalystsAvacta
ESMO 24: compelling data for AVA6000 and pre|CISIONArecor Therapeutics
EASD 2024: Positive Phase I for AT278 in Type II diabetes